{
    "id": 32683,
    "fullName": "MET H1094Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MET H1094Y (also referred to as H1112Y) lies within the protein kinase domain of the Met protein (UniProt.org). H1094Y leads to increased Met phosphorylation in cultured cells (PMID: 31911548, PMID: 10327054), and is associated with resistance to some MET and EGFR inhibitors (PMID: 31911548, PMID: 32034073).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1991,
                    "pubMedId": 10327054,
                    "title": "Novel mutations of the MET proto-oncogene in papillary renal carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10327054"
                },
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                },
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "H1094Y",
    "createDate": "03/03/2020",
    "updateDate": "03/03/2020",
    "referenceTranscriptCoordinates": {
        "id": 188173,
        "transcript": "NM_000245",
        "gDna": "chr7:g.116777409C>T",
        "cDna": "c.3280C>T",
        "protein": "p.H1094Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20710,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET H1094Y conferred resistance to Tagrisso (osimertinib) in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 31911548).",
            "molecularProfile": {
                "id": 35300,
                "profileName": "EGFR exon 19 del MET H1094Y"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20722,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Tagrisso (osimertinib) synergistically inhibited growth of a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion and expressing MET H1094Y in culture (PMID: 31911548).",
            "molecularProfile": {
                "id": 35300,
                "profileName": "EGFR exon 19 del MET H1094Y"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35292,
            "profileName": "MET H1094Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35300,
            "profileName": "EGFR exon 19 del MET H1094Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188173,
            "transcript": "NM_000245",
            "gDna": "chr7:g.116777409C>T",
            "cDna": "c.3280C>T",
            "protein": "p.H1094Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}